Filing Flows

Filing Flows › Caris Life Sciences (CAI) › Q1 2026

Caris Life Sciences (CAI) Q1 2026 earnings results (first quarter 2026)

10-Q filed May 8, 2026

Caris Life Sciences (CAI) reported revenue of $216M for the first quarter 2026 (Q1 2026), +79% from a year earlier and -26% from the quarter before. Operating margin was 2.4%, net loss $510K (0.2% of revenue).

Revenue$216M
Year over year+79%
Quarter over quarter-26%
Operating margin2.4%
Net earnings−$510K

Caris Life Sciences, Q1 2026: revenue $216M (+79% year over year), operating margin 2.4%, net loss $510K, operating cash flow $32.9M. The chart follows the revenue to costs, profit and cash.

Q1 2026AmountQ/QY/Y
Revenue$216M-26%+79%
Operating profit$5.3M-94%—
Net earnings−$510K-101%—
Operating cash flow$32.9M-27%—
Free cash flow$22.5M——

What changed

Revenue was $216.2M in Q1 2026, up 79% year over year and down 26% from the previous quarter. Molecular Profiling Services was the largest line at 98% of revenue. Molecular Profiling Services added $96.7M year over year (up 85%), 102% of the total change. Pharma Research and Development Services declined 21%.

Operating profit was $5.3M, a 2.4% margin (up 50.4 points year over year). Total costs grew 18% against revenue growth of 79%. The fastest-growing cost line was Research & development (+36%). The quarter ended with a net loss of $510K, after a profit of $82.0M the previous quarter. Net interest and other expense of $5.9M was the main reason.

Operating cash flow was $32.9M. Non-cash charges added back $5.1M of depreciation and amortization and $15.9M of share-based compensation. Working capital and other items added $12.4M. After purchases of property and equipment ($10.3M), free cash flow as the company reports it was $22.5M.

Questions

What was Caris Life Sciences' revenue in the first quarter 2026?

Caris Life Sciences (CAI) reported revenue of $216M for the first quarter 2026 (Q1 2026), +79% from a year earlier and -26% from the quarter before.

Was Caris Life Sciences profitable in the first quarter 2026?

Operating profit was $5.3M (2.4% of revenue) and net loss $510K.

Open the interactive Sankey →

Source: Caris Life Sciences 10-Q on SEC EDGAR.